SCHEMBL22723924

SCHEMBL22723924

COC(=O)C=C1C2CCC1CC(NC(=O)OC(C)(C)C)C2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 1/20 0.47
KMT2A Q03164 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
KDM1A O60341 2/20 0.44
MAOB P27338 1/20 0.44
GAA P10253 2/20 0.43
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
CTSK P43235 2/20 0.41
EPHX2 P34913 1/20 0.39
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
TYK2 P29597 1/20 0.38
JAK3 P52333 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CYP2C9 P11712 1/20 0.38
HSD11B1 P28845 1/20 0.38
CKS1B P61024 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9078331 0.79 NFKB1 (0.49) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL22961412 0.79 BTK (0.54) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL27872188 0.78 KDM1A (0.45) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL28527474 0.74 BTK (0.56) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL3702157 0.72 BTK (0.61) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL1406894 0.72 BTK (0.61) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL10343938 0.72 BTK (0.61) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL3702152 0.72 BTK (0.61) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL15365479 0.72 BTK (0.57) BTKKMT2AL3MBTL1KDM1AMAOB
SCHEMBL11901905 0.72 BTK (0.53) BTKKMT2AL3MBTL1KDM1AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11578084-B2 Condensed ring compounds having dopamine D3 receptor antagonistic effect SHIONOGI & CO., LTD. (JP) 2023-02-14 US disclosed
US-20210040117-A1 CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT SHIONOGI & CO., LTD. (JP) 2021-02-11 US disclosed
EP-3744721-A1 CONDENSED CYCLIC COMPOUND HAVING DOPAMINE D3 RECEPTOR ANTAGONISM Shionogi & Co., Ltd (JP) 2020-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210040117-A1 CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT DRD3, DRD2, DRD1 BTK 3107/4885KMT2A 1433/4885L3MBTL1 1684/4885
US-11578084-B2 Condensed ring compounds having dopamine D3 receptor antagonistic effect DRD3, DRD2, DRD1 BTK 3107/4885KMT2A 1433/4885L3MBTL1 1684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.